UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q
 (Mark One)
 
[X] 
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended January 31, 2019

or

[  ]
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from __________ to ___________

Commission file number: 000-53595

SUNWIN STEVIA INTERNATIONAL, INC.
(Exact name of registrant as specified in charter)

NEVADA
56-2416925
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
 
6 SHENGWANG AVE., QUFU, SHANDONG, CHINA
273100
(Address of principal executive offices)
(Zip Code)

(86) 537-4424999
(Registrant's telephone number, including area code)

NOT APPLICABLE
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes [X] No [  ]

Indicate by check mark whether the registrant has been submitted electronically and posted on its corporate Web site, if any, every Interactive Date File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  [  ]
Accelerated filer              [  ]
Non-accelerated filer    [  ]
Smaller reporting company  [X]
Emerging growth company [  ]
 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.   ☐  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X].

Indicate the number of shares outstanding of each of the issuer's classes of common equity as of the latest practicable date: As of March 15, 2019, there were 199,632,803 shares of the registrant's common stock issued and outstanding.

SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES
FORM 10-Q
  QUARTERLY PERIOD ENDED JANUARY 31, 2019
 
INDEX
 
 
Page
PART I-FINANCIAL INFORMATION
 
 
 
Item 1.    Financial Statements
1
 
 
Item 2.    Management's Discussion and Analysis of Financial Condition and Results of Operations
18
 
 
Item 3.    Quantitative and Qualitative Disclosures About Market Risk
26
 
 
Item 4.    Controls and Procedures
26
 
 
PART II-OTHER INFORMATION
 
 
Item 1.    Legal Proceedings
27
 
 
Item 1A.  Risk Factors
27
 
 
Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds
27
 
 
Item 3.     Defaults Upon Senior Securities
27
 
 
Item 4.     Mine Safety Disclosures
28
 
 
Item 5.     Other Information
28
 
 
Item 6.     Exhibits
28

i


FORWARD LOOKING STATEMENTS

This report contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements, but are not deemed to represent an all-inclusive means of identifying forward-looking statements as denoted in this report. Additionally, statements concerning future matters are forward-looking statements . 

Although forward-looking statements in this report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under the headings "Risks Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our annual report on Form 10-K, in "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Form 10-Q and information contained in other reports that we file with the SEC. You are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this report . 

We file reports with the SEC. The SEC maintains a website (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us. You can also read and copy any materials we file with the SEC at the SEC's Public Reference Room at 100 F Street, NE, Washington, DC 20549. You can obtain additional information about the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330 . 

We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this report, except as required by law. Readers are urged to carefully review and consider the various disclosures made throughout the entirety of this quarterly report, which are designed to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects .

ii


INDEX OF CERTAIN DEFINED TERMS USED IN THIS REPORT

We are on a fiscal year ending April 30, as such the year ending April 30, 2019 is referred to as "fiscal 2019" and the year ended April 30, 2018 is referred to as "fiscal 2018".  Also, the three month period ended January 31, 2019 is our third quarter and is referred to as the "third quarter of fiscal 2019". Likewise, the three month period ended January 31, 2018 is referred to as the "third quarter of fiscal 2018".

  When used in this report, the terms:
 
 
-
 
"Sunwin", "we", "us" and the "Company" refers to Sunwin Stevia International, Inc., a Nevada corporation formerly known as Sunwin Neutraceuticals International, Inc., and our subsidiaries;
 
-
 
"Sunwin Tech" refers to our wholly owned subsidiary Sunwin Tech Group, Inc., a Florida corporation, which was closed on April 30, 2018 and all of assets and liabilities were transferred to the Company;
 
-
 
"Qufu Natural Green" refers to our wholly owned subsidiary Qufu Natural Green Engineering Co., Ltd., a Chinese limited liability company;
 
-
 
"Sunwin USA" refers to Sunwin USA, LLC, a Delaware limited liability company, a 100% owned subsidiary of Sunwin. Sunwin USA was previously known as Sunwin Stevia International Corp., a Florida corporation, it was converted to Sunwin USA in May 2009;
 
-
 
"Qufu Shengwang" refers to Qufu Shengwang Stevia Biology and Science Co., Ltd., a Chinese limited liability company. Qufu Natural Green owns a 100% interest in Qufu Shengwang; and 
 
-
 
"Qufu Shengren" refers to Qufu Shengren Pharmaceutical Co., Ltd., a Chinese limited liability company, and a wholly owned subsidiary of Qufu Natural Green.
 
 
 
 
  We also use the following terms when referring to certain related parties:
 
 
-
 
"Pharmaceutical Corporation" refers to Shandong Shengwang Pharmaceutical Co., Ltd., a Chinese limited liability company which is controlled by Mr. Laiwang Zhang, Chairman and a principal shareholder of our Company;
 
-
 
"Qufu Shengwang Import and Export" refers to Qufu Shengwang Import and Export Co., Ltd., a Chinese limited liability company, controlled by Mr. Zhang;
 
-
 
"Shandong Group" refers to Shandong Shengwang Group Co., Ltd., a Chinese limited liability company, controlled by Mr. Zhang; and
 
-
 
Mr. Weidong Chai, a management member of Qufu Shengren Pharmaceutical Co., Ltd.
 
 The information which appears on our website at www.sunwininternational.com is not part of this report.
iii

PART I - FINANCIAL INFORMATION
 
SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES
 
CONDENSED CONSOLIDATED BALANCE SHEETS
 
   
 
 
January 31,
2019
   
April 30,
2018
 
 
 
(Unaudited)
       
ASSETS
           
CURRENT ASSETS:
           
Cash and cash equivalents
 
$
155,694
   
$
1,100,748
 
Accounts receivable, net of allowance for doubtful accounts of $180,042 and $191,865, respectively
   
2,876,542
     
3,513,530
 
Accounts receivable - related parties
   
2,287,466
     
2,576,944
 
Inventories, net
   
13,415,941
     
12,564,571
 
Prepaid expenses and other current assets
   
2,658,517
     
2,284,379
 
 
               
Total Current Assets
   
21,394,160
     
22,040,172
 
 
               
Property and equipment, net
   
10,016,429
     
9,052,886
 
Land use rights, net
   
1,816,806
     
1,964,606
 
Other long-term asset
   
145,370
     
153,720
 
 
               
     Total Assets
 
$
33,372,765
   
$
33,211,384
 
 
               
LIABILITIES AND STOCKHOLDERS' EQUITY
               
CURRENT LIABILITIES:
               
Accounts payable and accrued expenses
 
$
9,703,167
   
$
11,660,004
 
Short-term loans
   
9,160,988
     
8,302,489
 
Due to related parties
   
3,516,081
     
2,559,216
 
 
               
    Total Current Liabilities
   
22,380,236
     
22,521,709
 
 
               
Long-term loans
   
5,832,774
     
1,687,857
 
 
               
  Total Liabilities 
   
28,213,010
     
24,209,566
 
 
               
Commitments and Contingencies
               
 
               
STOCKHOLDERS' EQUITY:
               
Preferred stock, $0.001 par value; 1,000,000 shares authorized; no shares issued and outstanding
   
-
     
-
 
Common stock, $0.001 par value, 200,000,000 shares authorized; 199,632,803 and 199,632,803 shares issued and outstanding as of January 31, 2019 and April 30, 2018, respectively
   
199,633
     
199,633
 
Additional paid-in capital
   
37,681,279
     
37,681,279
 
Accumulated deficit
   
(37,141,761
)
   
(33,827,351
)
Accumulated other comprehensive income
   
4,420,604
     
4,948,257
 
    Total Stockholders' Equity
   
5,159,755
     
9,001,818
 
      Total Liabilities and Stockholders' Equity
 
$
33,372,765
   
$
33,211,384
 
 
               
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements
 

- 1 -


SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES
 
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
 
(UNAUDITED)
 
   
  
 
For the Three Months Ended
January 31,
   
For the Nine Months Ended
January 31,
 
 
 
2019
   
2018
   
2019
   
2018
 
 
                       
Revenues
 
$
5,281,215
   
$
4,734,263
   
$
14,356,459
   
$
13,234,376
 
Revenues - related parties
   
1,086,794
     
1,591,329
     
3,206,484
     
1,858,709
 
Total revenues
   
6,368,009
     
6,325,592
     
17,562,943
     
15,093,085
 
 
                               
Cost of revenues
   
4,290,907
     
3,893,338
     
12,407,123
     
11,908,831
 
Cost of revenues - related parties
   
1,127,662
     
1,605,388
     
3,029,909
     
1,878,662
 
Total cost of revenues
   
5,418,569
     
5,588,776
     
15,437,032
     
13,787,493
 
 
                               
Gross profit
   
949,440
     
736,816
     
2,125,911
     
1,305,592
 
 
                               
Operating expenses:
                               
Selling expenses
   
721,309
     
592,042
     
1,871,621
     
1,447,692
 
General and administrative expenses
   
724,652
     
774,387
     
2,268,427
     
2,513,984
 
Loss on disposition of property and equipment
   
-
     
2,430
     
-
     
285,150
 
Research and development expenses
   
319,747
     
284,351
     
702,883
     
650,654
 
Total operating expenses, net
   
1,765,708
     
1,653,210
     
4,842,931
     
4,897,480
 
 
                               
Loss from operations
   
(816,268
)
   
(916,394
)
   
(2,717,020
)
   
(3,591,888
)
 
                               
Other income (expenses)
                               
 
                               
Other income (expenses)
   
4,746
     
195,253
     
(8,416
)     
156,906
 
Interest income
   
352
     
414
     
1,213
     
785
 
Interest expense - related parties
   
(35,855
)
   
(25,945
)
   
(101,546
)
   
(71,135
)
Interest expense
   
(171,705
)
   
(126,138
)
   
(488,641
)
   
(316,578
)
 
                               
Total other ( expenses) income
   
(202,462
)
   
43,584
     
(597,390
)
   
(230,022
)
 
                               
Loss before income taxes
   
(1,018,730
)
   
(872,810
)
   
(3,314,410
)
   
(3,821,910
)
 
                               
Provision for income taxes
   
-
     
-
     
-
     
-
 
 
                               
Net loss
 
$
(1,018,730
)
 
$
(872,810
)
 
$
(3,314,410
)
 
$
(3,821,910
)
 
                               
Comprehensive loss:
                               
Net loss
 
$
(1,018,730
)
 
$
(872,810
)
 
$
(3,314,410
)
 
$
(3,821,910
)
 
                               
Foreign currency translation adjustment
   
261,034
     
532,476
     
(527,653
)
   
969,730
 
 
                               
Total comprehensive loss
 
$
(757,696
)
 
$
(340,334
)
 
$
(3,842,063
)
 
$
(2,852,180
)
 
                               
Net loss per common share:
                               
Net loss per share - basic and diluted
 
$
(0.01
)
 
$
(0.00
)
 
$
(0.02
)
 
$
(0.02
)
Weighted average common shares outstanding - basic and diluted
   
199,632,803
     
199,632,803
     
199,632,803
     
199,632,803
 
 
                               
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements
 
- 2 -


SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES
 
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
 
(UNAUDITED)
 
   
 
 
For the Nine Months Ended
January 31,
 
 
 
2019
   
2018
 
CASH FLOWS FROM OPERATING ACTIVITIES:
           
Net loss
 
$
(3,314,410
)
 
$
(3,821,910
)
Adjustments to reconcile net loss to net cash used in operating activities:
               
  Depreciation expense
   
902,237
     
1,054,856
 
  Amortization of intangible assets
   
-
     
108,390
 
  Amortization of land use right
   
39,207
     
39,736
 
 Stock issued for employees' compensation
   
715,553
     
920,001
 
 Loss on disposition of property and equipment
   
-
     
285,150
 
 Recovery of bad debt reserve
   
-
     
(216,910
)
Changes in operating assets and liabilities:
               
  Accounts receivable and notes receivable
   
503,773
     
(261,918
)
  Accounts receivable - related parties
   
148,367
     
(1,988,620
)
  Inventories
   
(1,522,075
)
   
(2,301,254
)
  Prepaid expenses and other current assets
   
(1,226,946
)
   
1,715,157
 
  Accounts payable and accrued expenses
   
(2,866,962
)
   
2,062,513
 
  Taxes payable
   
(68,570
)
   
(37,968
)
NET CASH USED IN OPERATING ACTIVITIES
   
(6,689,826
)
   
(2,442,777
)
 
               
CASH FLOWS FROM INVESTING ACTIVITIES:
               
Purchases of property and equipment
   
(716,188
)
   
(707,890
)
Proceed from disposal of equipment
   
-
     
1,505
 
NET CASH USED IN INVESTING ACTIVITIES
   
(716,188
)
   
(706,385
)
 
               
CASH FLOWS FROM FINANCING ACTIVITIES:
               
Proceeds from loans
   
5,788,134
     
1,665,342
 
Repayment of short term loans
   
(429,299
)
   
(375,077
)
Advances due from related parties
   
3,946,954
     
5,068,601
 
Repayment of related party advances
   
(2,923,479
)
   
(3,251,990
)
NET CASH PROVIDED BY FINANCING ACTIVITIES
   
6,382,310
     
3,106,876
 
 
               
EFFECT OF EXCHANGE RATE ON CASH
   
78,650
     
142,299
 
NET (DECREASE) INCREASE IN CASH
   
(945,054
)
   
100,013
 
 
               
Cash at the beginning of period
   
1,100,748
     
51,116
 
Cash at the end of period
 
$
155,694
   
$
151,129
 
 
               
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
               
  Cash paid for income taxes
 
$
-
   
$
-
 
  Cash paid for interest
 
$
80,675
   
$
38, 484
 
 
               
NON-CASH INVESTING AND FINANCING ACTIVITIES:
               
  Property and equipment acquired on credit as payable
 
$
1,622,879
   
$
28,024
 
  Accrued interest enrolled into debt
 
$
144,761
   
$
132,747
 
  Accrued interest payable to related party
 
$
39,776
   
$
-
 
 
               
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements
 
- 3 -


SUNWIN STEVIA INTERNATIONAL, INC. AND SUBSIDIARIES
 NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
JANUARY 31, 2019

NOTE 1 - ORGANIZATION AND OPERATIONS
 
DESCRIPTION OF BUSINESS

Sunwin Stevia International, Inc. ("Sunwin Stevia International"), a Nevada corporation, and its subsidiaries are referred to in this report as "we", "us", "our", "Sunwin" or the "Company".

We sell stevioside, a natural sweetener, as well as herbs used in traditional Chinese medicines and veterinary products. Substantially all of our operations are located in the People's Republic of China (the "PRC"). We have built an integrated company with the sourcing and production capabilities designed to meet the needs of our customers.

Our operations are organized into two product segments, our Stevioside and Chinese Medicine product lines, and subsidiaries included in continuing operations consisted of the following:

-    Sunwin Stevia International;
-   Qufu Natural Green Engineering Co., Ltd. ("Qufu Natural Green"), wholly owned by Sunwin Stevia International;
-   Qufu Shengren Pharmaceutical Co., Ltd. ("Qufu Shengren"), wholly owned by Qufu Natural Green;
-   Qufu Shengwang Stevia Biology and Science Co., Ltd. ("Qufu Shengwang"), wholly owned by Qufu Natural Green; and
-   Sunwin USA, LLC ("Sunwin USA"), wholly owned by Sunwin Stevia International.

Stevioside Segment

In our Stevioside segment, we produce and sell a variety of purified steviol glycosides with rebaudioside A and stevioside as the principal components, an all natural, low calorie sweetener, and OnlySweet, a stevioside based table top sweetener.

Chinese Medicine Segment

In our Chinese Medicine Segment, we manufacture and sell a variety of traditional Chinese medicine formula extracts which are used in products made for use by both humans and animals.

Qufu Shengwang

In fiscal 2009, Qufu Natural Green acquired a 60% interest in Qufu Shengwang from its shareholder, Shandong Group, for $4,026,851. The purchase price represented 60% of the value of the net tangible assets of Qufu Shengwang as of April 30, 2008. Shandong Group is owned by Laiwang Zhang, our President and Chairman of the Board of Directors. Qufu Shengwang manufactures and sells stevia - based fertilizers and feed additives.

On September 30, 2011, Qufu Natural Green purchased the 40% equity interest in Qufu Shengwang owned by our Korean partner, Korea Stevia Company, Limited, for $626,125 in cash, and as a result of this repurchase transaction we now own 100% equity interest in all of the net assets of our subsidiary Qufu Shengwang.

On July 1, 2012, Qufu Shengwang entered a Cooperation Agreement with Hegeng (Beijing) Organic Farm Technology Co, Ltd. ("Hegeng"), a Chinese manufacturer and distributor of bio-fertilizers and pesticides, to jointly develop bio-bacterial fertilizers based on the residues from our stevia extraction. Under the Cooperation Agreement, Hegeng provides strain and formula that we apply to the stevia residues to produce bio-bacterial fertilizers in the current facility of Qufu Shengwang. The bio-bacterial fertilizers will be distributed under Qufu Shengwang's name.  No additional investment in the facility would be required. During the third quarter of fiscal 2013, we decided to suspend the agreement with Hegeng due to a lack of sales since the reaction to the products was lower than anticipated in the fertilizer market. Currently we plan to use these assets to manufacture a variety of traditional Chinese medicine formula extracts. We started production in last quarter of fiscal 2014.
- 4 -


Qufu Shengren

In fiscal 2009, Qufu Natural Green acquired Qufu Shengren for $3,097,242. The purchase price was equal to the value of the assets of Qufu Shengren as determined by an independent asset appraisal in accordance with asset appraisal principles in the PRC. Prior to being acquired by us, Qufu Shengren was engaged in the production and distribution of bulk drugs and pharmaceuticals.  Subsequent to the acquisition, Qufu Shengren produces and distributes steviosides with a full range of grades from rebaudioside-A 10 to 99.
 
Sunwin USA

In fiscal 2009, we entered into a distribution agreement with WILD Flavors to assist our 55% owned subsidiary, Sunwin USA, in the marketing and worldwide distribution of our stevioside-based sweetener products and issued WILD Flavors a 45% interest in Sunwin USA. 
 
On August 8, 2012, we entered into an Exchange Agreement with WILD Flavors pursuant to which we purchased its 45% membership interest in Sunwin USA for an aggregate consideration of approximately $1,625,874, which includes the issuance of 7,666,666 shares of our common stock valued at approximately $1,533,333 and a cash payment of $92,541. The transaction closed on August 20, 2012. On August 22, 2012, we issued 7,666,666 shares of our common stock and paid $92,541 cash to WILD Flavors.   The net tangible assets of Sunwin USA were reduced from $1,825,804 to $1,625,874 as a result of the application of generally accepted accounting principles ("U.S. GAAP") which requires elimination of the difference between the purchase price of the 45% membership interest in Sunwin USA and cost basis of the intangible assets recorded by Sunwin USA. Intangible assets include the product development and supply chain for OnlySweet.

Under the terms of the agreement, WILD Flavors assumed certain pre-closing obligations of Sunwin USA totaling approximately $694,000, including trade accounts receivable, loans, health care and monthly expenses of an employee, potential chargebacks, bank fees and broker commissions incurred prior to the closing date. The agreement also contained customary joint indemnification and general releases.  As a result of this transaction, we began consolidating the operations of Sunwin USA from the date of acquisition (August 20, 2012).

In addition to the Exchange Agreement, on August 8, 2012 we entered into the following additional agreements with WILD Flavors or its affiliate:

-     We entered into an Amendment to Operating Agreement with WILD Flavors pursuant to which we are now the sole management of Sunwin USA and certain sections of the original agreement dated April 29, 2009 were cancelled as they were no longer relevant following our purchase of the minority interest in Sunwin USA described above;

-     We entered into a Termination of Distribution Agreement with WILD Flavors and Sunwin USA pursuant to which the Distribution Agreement dated February 5, 2009 was terminated; and
 
-    We entered into a Distributorship Agreement with WILD Procurement Gmbh, a Swiss corporation ("WILD Procurement") which is an affiliate of WILD Flavors. Under the terms of this agreement, we appointed WILD Procurement as a non-exclusive world-wide distributor for the resale of our stevia products.  There are no minimum purchase quantities under the agreement, and the pricing and terms of each order will be negotiated by the parties at the time each purchase order is placed.  The agreement restricts WILD Procurement from purchasing steviosides or other forms of stevia that are included in our products from sources other than our company under certain circumstances. In addition, at such time as we desire to offer new products, we must first offer WILD Procurement the non-exclusive right to distribute those products and the parties will have 60 days to reach mutually agreeable terms. The agreement contains certain representations by us as to the quality of the products we may sell WILD Procurement and the products' compliance with applicable laws and good manufacturing practices, as well as customary confidentiality and indemnification provisions.

In the event WILD Procurement should fund research on stevia used in food, beverage or dietary supplement applications, and as a result of this research it develops new intellectual property, such intellectual property shall be the sole property of WILD Procurement. In the event we should jointly fund research, any new intellectual property developed from this effort will be jointly owned and each party will have the right to use the developed intellectual property in stevia-based products.
- 5 -


The agreement is for an initial term of 12 months and will automatically renew for successive 12 month terms unless the agreement has been terminated by either party upon 45 days prior written notice. There are no assurances any purchase orders will be placed under the terms of the Distribution Agreement. The agreement may also be terminated by either party upon a material breach by the other party, or upon the filing of a bankruptcy petition, both subject to certain cure periods. In the event the agreement is terminated, WILD Procurement has the right to continue to distribute our products on a non-exclusive basis for 24 months upon terms and conditions to be negotiated by the parties. Currently, WILD still is one of our customers continuing to purchase enzyme treated products from us.
 
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements include the accounts of Sunwin and all our wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC") for interim financial reporting. The accompanying unaudited condensed consolidated financial statements for the interim periods presented are unaudited and reflect all adjustments (consisting only of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the periods presented. Certain financial statement amounts relating to prior periods have been reclassified to conform to the current period presentation. All intercompany accounts and transactions have been eliminated in consolidation.

These unaudited condensed consolidated interim financial statements should be read in conjunction with the financial statements and footnotes for the year ended April 30, 2018 included in our Form 10-K as filed with the SEC. The results of operations and cash flows for the nine months ended January 31, 2019 are not necessarily indicative of the results of operations or cash flows which may be reported for future periods or the full fiscal year.

The condensed consolidated balance sheet as of April 30, 2018 contained herein has been derived from the audited consolidated financial statements as of April 30, 2018, but do not include all disclosures required by the U.S. GAAP.
 
Our unaudited condensed consolidated financial statements include the accounts of Sunwin and all our wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Our subsidiaries include the following:
 
-     Qufu Natural Green;
-     Qufu Shengren;
-     Qufu Shengwang; and
-     Sunwin USA
 
USE OF ESTIMATES

The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the allowance for doubtful accounts, the allowance for obsolete inventory, the useful life of property and equipment and intangible assets, assumptions used in assessing impairment of long-term assets and valuation of deferred tax assets, and the value of stock-based compensation.  Actual results could differ from those estimates.

CASH AND CASH EQUIVALENTS

We consider all highly liquid investments with maturities of nine months or less at the time of purchase to be cash and equivalents. As of January 31, 2019, we held $57,188 of our cash and cash equivalents with commercial banking institutions in the PRC, and $98,506 with banks in the United States. As of April 30, 2018, we held $1,100,052 of our cash and cash equivalents with commercial banking institution in PRC, and $696 in the United States. In China, there is no equivalent federal deposit insurance as in the United States, so the amounts held in banks in China are not insured. We have not experienced any losses in such bank accounts through January 31, 2019.
 
- 6 -

ACCOUNTS RECEIVABLE

Accounts receivable and other receivable are reported at net realizable value. We have established an allowance for doubtful accounts based upon factors pertaining to the credit risk of specific customers, historical trends, and other information. Delinquent accounts are written off when it is determined that the amounts are uncollectible after exhaustive efforts on collection. As of January 31, 2019 and April 30, 2018, the allowance for doubtful accounts was $180,042 and $191,865, respectively.

INVENTORIES

Inventories, consisting of raw materials, work in process, and finished goods related to our products, are stated at the lower of cost and net realizable value that can be estimated utilizing the weighted average method. A reserve is established when management determines that certain slow-moving inventories may be sold at below book value.  These reserves are recorded based on estimates. As of January 31, 2019 and April 30, 2018, the Company did not record a reserve for obsolete or slow-moving inventories. If inventory costs exceed expected market value due to obsolescence or quantities in excess of expected demand, the Company will record a write down inventories for the difference between the cost or estimated net realizable value. As of January 31, 2019 and April 30, 2018, the Company wrote down inventories of $22,765 and $235,258, respectively.
 
PROPERTY AND EQUIPMENT

Property and equipment are stated at cost. Depreciation and amortization are provided using the straight line method over the estimated economic lives of the assets, which range from three to twenty years. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized. Expenditures for maintenance and repairs are charged to expense as incurred. In accordance with paragraph 360-10-35-17 of the Financial Accounting Standards Board (FASB) Accounting Standards Codification ("ASC"), we examine the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable.

Included in property and equipment is construction-in-progress which consisted of factory improvements and machinery pending installation and included the costs of construction, machinery and equipment, and or any interest charges arising from borrowings used to finance these assets during the period of construction or installation of the assets if applicable. No provision for depreciation is made on construction-in-progress until such time as the relevant assets are completed and ready for their intended use.

LONG-LIVED ASSETS

In accordance with ASC 360, we review and evaluate our long-lived assets, including property and equipment, intangible assets, and land use rights, for impairment or when events or changes in circumstances indicate that the related carrying amounts may not be recoverable. An impairment is considered to exist if the total estimated future cash flows on an undiscounted basis are less than the carrying amount of the assets, including goodwill, if any. An impairment loss is measured and recorded based on discounted estimated future cash flows. In estimating future cash flows, assets are grouped at the lowest level for which there is identifiable cash flows that are largely independent of future cash flows from other asset groups. Our estimates of future cash flows are based on numerous assumptions and it is possible that actual future cash flows will be significantly different than the estimates. Based on our evaluation, we have determined certain long-lived assets that are no longer useful for our operations, and we recorded a loss on disposition of property and equipment of $0 and $2,430, $0 and $285,150 for the three and nine months ended Jan 31, 2019 and 2018, respectively.

FAIR VALUE OF FINANCIAL INSTRUMENTS

We adopted ASC Section 820-10-35-37 to measure the fair value of our financial instruments. ASC Section 820-10-35-37 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements, establishes a framework for measuring fair value, and expands disclosure about such fair value measurements. The adoption of ASC Section 820-10-35-37 did not have an impact on our financial position or operating results, but did expand certain disclosures.
 
ASC Section 820-10-35-37 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC Section 820-10-35-37 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

Level 1:
Observable inputs such as quoted market prices in active markets for identical assets or liabilities
Level 2:
Observable market-based inputs or unobservable inputs that are corroborated by market data
Level 3:
Unobservable inputs for which there is little or no market data, which require the use of the reporting entity's own assumptions.
 
The carrying amounts of our financial assets and liabilities, such as cash, accounts receivable, notes receivable, prepayments and other current assets, accounts payable, taxes payable and accrued expenses, approximate their fair values because of the short maturity of these instruments.  
 
- 7 -

TAXES PAYABLE

We are required to charge for and to collect value added taxes (VAT) on our sales on behalf of the PRC tax authority. We record VAT that we billed our customers as VAT payable. In addition, we are required to pay value added taxes on our primary purchases. We record VAT that is charged by our vendors as VAT receivable. We are required to file VAT returns on a monthly basis with the PRC tax authority, which we are entitled to claim the VAT that we are charged by vendors as VAT credit and these credits can be applied to our VAT payable that we billed our customers. Accordingly, these VAT payable and receivable are presented as net amounts for financial statement purposes. Taxes payable as of January 31, 2019 and April 30, 2018 amounted to $119,701 and $199,644, respectively, consisted primarily of VAT taxes.

REVENUE RECOGNITION
 
Pursuant to the guidance of ASC Topic 606, we record revenue when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers.
 
INCOME TAXES
 
The Company has adopted Accounting Standards Codification subtopic 740-10, Income Taxes ("ASC 740-10") which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns.  Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.  Valuation allowances are recorded to reduce the deferred tax assets to an amount that it is more likely than not be realized.

We file federal and state income tax returns in the United States for our corporate operations pursuant to the U.S. Internal Revenue Code of 1986, as amended, and file separate foreign tax returns for our Chinese subsidiaries pursuant to the China's Unified Corporate Income Tax Law.
 
We apply the provisions of ASC 740-10-50, "Accounting for Uncertainty in Income Taxes", which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our condensed consolidated financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company's liability for income taxes. Any such adjustment could be material to the Company's results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of January 31, 2019, the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.
 
BASIC AND DILUTED EARNINGS PER SHARE

Pursuant to ASC Section 260-10-45, basic loss per common share is computed by dividing loss available to common shareholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income of ours, subject to anti-dilution limitations. The following table presents a reconciliation of basic and diluted net income per common share:

 
 
Three Months Ended
January 31,
   
Nine Months Ended
January 31,
 
Numerator:
 
2019
   
2018
   
2019
   
2018
 
Net loss attributable to Sunwin Stevia International, Inc.
 
$
(1,018,730
)
 
$
(872,810
)
 
$
(3,314,410
)
 
$
(3,821,910
)
Numerator for basic EPS, loss applicable to common stock holders
 
$
(1,018,730
)
 
$
(872,810
)
 
$
(3,314,410
)
 
$
(3,821,910
)
Denominator:
                               
Denominator for basic earnings per share - weighted average number of common shares outstanding
   
199,632,803
     
199,632,803
     
199,632,803
     
199,632,803
 
Stock awards, options, and warrants
   
-
     
-
     
-
     
-
 
Denominator for diluted earnings per share - adjusted weighted average outstanding average number of common shares outstanding
   
199,632,803
     
199,632,803
     
199,632,803
     
199,632,803
 
Basic and diluted loss per common share:
                               
Loss per share - basic and diluted
 
$
(0.01
)
 
$
(0.00
)
 
$
(0.02
)
 
$
(0.02
)
 
- 8 -

  FOREIGN CURRENCY TRANSLATION

Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Transactions and balances in other currencies are converted into U.S. dollars in accordance with ASC Section 830-20-35 and are included in determining net income or loss. 

The reporting currency of the Company is the U.S. dollar. The functional currency of the parent company is the U.S. dollar and the functional currency of the Company's operating subsidiaries is the Chinese Renminbi ("RMB").  In accordance with ASC 830-20-35, the consolidated financial statements were translated into United States dollars using balance sheet date rates of exchange for assets and liabilities, and average rates of exchange for the period for the income statements and cash flows. Equity accounts were stated at their historical rate. Net gains and losses resulting from foreign exchange transactions are included in the condensed consolidated statements of operations.  Translation adjustments resulting from the process of translating the local currency financial statements into U.S. dollars are included in other comprehensive income or loss.
 
RMB is not a fully convertible currency. All foreign exchange transactions involving RMB must take place either through the People's Bank of China (the "PBOC") or other institutions authorized to buy and sell foreign exchange. The exchange rate adopted for the foreign exchange transactions are the rates of exchange quoted by the PBOC, which are determined largely by supply and demand. Translation of amounts from RMB into United States dollars ("$") was made at the following exchange rates for the respective periods:
 
As of January 31, 2019
RMB 6.70 to $1.00
As of April 30, 2018
RMB 6.33 to $1.00
 
 
Nine months ended January 31, 2019
RMB 6.76 to $1.00
Nine months ended January 31, 2018
RMB 6.67 to $1.00
 
COMPREHENSIVE LOSS
 
Comprehensive loss is comprised of net loss and all changes to the statements of stockholders' equity, except those due to investments by stockholders, changes in paid-in capital and distributions to stockholders. For the Company, comprehensive loss for the three and nine months ended January 31, 2019 and 2018 included net loss and unrealized gains (losses) from foreign currency translation adjustments. 

CONCENTRATIONS OF CREDIT RISK

Substantially all of our operations are carried out in the PRC. Accordingly, our business, financial condition and results of operations may be influenced by the political, economic and legal environment in the PRC, and by the general state of the PRC's economy. Our operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in North America. Our results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

Financial instruments which potentially subject us to concentrations of credit risk consist principally of cash and trade accounts receivable. We place our cash with high credit quality financial institutions in the United States and China. As of January 31, 2019, we had $57,188 of our cash and cash equivalents with commercial banking institutions in the PRC, and $98,506 with banks in the United States. As of April 30, 2018, we held $1,100,052 of our cash and cash equivalents with commercial banking institution in PRC, and $696 in the United States. In China, there is no equivalent federal deposit insurance as in the United States, so the amounts held in banks in China are not insured. We have not experienced any losses in such accounts through January 31, 2019.

Almost all of our sales are credit sales which are primarily to customers whose ability to pay is dependent upon the industry economics prevailing in these areas; however, we believe that the concentration of credit risk with respect to trade accounts receivable is limited due to generally short payment terms. We also perform ongoing credit evaluations of our customers to help further reduce potential credit risk.
 
STOCK BASED COMPENSTION
 
Stock-based compensation is accounted for based on the requirements of the Share-Based Payment topic of ASC 718 which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). ASC 718 also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award
 
- 9 -

 
RESEARCH AND DEVELOPMENT
 
Research and development costs are expensed as incurred and are included in general and administrative expenses in the accompanying statements of operations. Research and development costs are incurred on a project specific basis. Research and development cost were $319,747 and $284,351 for the three months ended January 31, 2019 and 2018, and $702,883 and $650,654 for the nine months ended January 31, 2019 and 2018, respectively.
 
SHIPPING COSTS

Shipping costs are included in selling expenses and totaled $72,937 and $82,237 for the three months ended January 31, 2019 and 2018, and $235,984 and $244,488 for the nine months ended January 31, 2019 and 2018, respectively.
 
ADVERTISING
          Advertising is expensed as incurred and is included in selling expenses. Advertising expenses totaled $181,336 and $12,755 for the three months ended January 31, 2019 and 2018, and $235,309 and $53,882 for the nine months ended January 31, 2019 and 2018, respectively.   

RECLASSIFICATIONS

Certain prior year amounts have been reclassified to conform to the current period presentation. These reclassifications had no impact on net earnings and financial position.
 
SEGMENT REPORTING

The Company uses the "management approach" in determining reportable operating segments. The management approach considers the internal organization and reporting used by the Company's chief operating decision maker for making operating decisions and assessing performance as the source for determining the Company's reportable segments. The Company's chief operating decision maker has been identified as the chief executive officer of the Company who reviews financial information of separate operating segments based on U.S. GAAP. The chief operating decision maker now reviews results analyzed by customer. This analysis is only presented at the revenue level with no allocation of direct or indirect costs. Consequently, the Company has determined that it has only one operating segment.

RECENT ACCOUNTING PRONOUNCEMENTS

In May 2014, the FASB issued ASU 2014-09, " Revenue from contracts with Customers (Topic 606) ". Under ASU 2014-09, revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. This standard, which is effective for interim and annual reporting periods in fiscal years that begin after December 15, 2017. The guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (modified retrospective method). The Company adopted this standard effective May 1, 2018 by using the full retrospective method to restate prior reporting period presented. The Company has identified its revenue streams and assessed each for the impacts. The Company completed its analysis and concluded that the adoption of Topic 606 did not have a material impact in the timing or amount of revenue recognized, including the presentation of revenues in the Company's consolidated statements of income and comprehensive loss.
 
In February 2018, the FASB issued ASU 2018-02, "Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income". These amendments provide financial statement preparers with an option to reclassify stranded tax effects within accumulated other comprehensive income to retained earnings in each period in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Cuts and Jobs Act (or portion thereof) is recorded. The amendments in this ASU are effective for all entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption of ASU 2018-02 is permitted, including adoption in any interim period for the public business entities for reporting periods for which financial statements have not yet been issued. The amendments in this ASU should be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Cuts and Jobs Act is recognized. The Company is currently evaluating the impact of the adoption of ASU No. 2018-02 on its consolidated financial statements.
 
In March 2018, the FASB issued ASU 2018-05, "Income Taxes (Topic 740) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118". The amendments in this ASU add SEC paragraphs pursuant to the SEC Staff Accounting Bulletin No. 118, which expresses the view of the staff regarding application of Topic 740, Income Taxes, in the reporting period that includes December 22, 2017 - the date on which the Tax Cuts and Jobs Act was signed into law. The amendments are effective upon addition to the FASB Accounting Standards Codification. The adoption of this guidance is not expected to have a material impact on our consolidated financial statements.

A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, we have not determined whether implementation of such proposed standards would be material to our consolidated financial statements.

- 10 -

GOING CONCERN
 
Our unaudited condensed consolidated financial statements have been prepared assuming we will continue as a going concern.  The Company has incurred recurring loss with a net loss of approximately $1,019,000 and $3,314,000 for the three and nine months ended January 31, 2019, respectively, and has a significant accumulated deficit of $37.1 million as of January 31, 2019. The Company's cash balance and revenues generated are not currently sufficient and cannot be projected to cover operating expenses for the next twelve months from the date of this report. These factors raise doubt as to the ability of the Company to continue as a going concern. Management's plans include attempting to improve its business profitability, its ability to generate sufficient cash flow from its operations to meet its operating needs on a timely basis, obtain additional working capital funds through debt and equity financings, and restructure on-going operations to eliminate inefficiencies to raise cash balance in order to meet its anticipated cash requirements for the next twelve months from the date of this report. Management intends to make every effort to improve its current sales force as to further develop and expand the international markets for its new products as well as continuing with the current sources of funds to meet working capital needs on as needed basis.  There can be no assurance that these plans and arrangements will be successful.

The ability of the Company to continue as a going concern is dependent upon its ability to achieve profitable operations and raise additional capital. The accompanying unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amount or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.
 
NOTE 3 - INVENTORIES

As of January 31, 2019 and April 30, 2018, inventories consisted of the following:
  
 
 
January 31,
2019
   
April 30,
2018
 
 
 
(unaudited)
       
Raw materials
 
$
5,477,559
   
$
8,803,685
 
Work in process
   
4,030,657
     
1,357,484
 
Finished goods
   
3,907,725
     
2,403,402
 
 
 
$
13,415,941
   
$
12,564,571
 

NOTE 4 - PROPERTY AND EQUIPMENT

As of January 31, 2019 and April 30, 2018, property and equipment consisted of the following:

 
 
January 31,
2019
   
April 30,
2018
 
Estimated Life 
 
(unaudited)
       
Office equipment
3-10 Years
 
$
103,192
   
$
75,821
 
Auto and trucks
2-10 Years
   
617,001
     
660,926
 
Manufacturing equipment
2-20 Years
   
5,800,661
     
5,638,206
 
Buildings
5-20 Years
   
9,260,118
     
9,224,911
 
Construction in process
 
   
1,922,325
     
661,111
 
 
 
   
17,703,297
     
16,260,975
 
Less: accumulated depreciation
 
   
(7,686,868
)
   
(7,208,089
)
 
    
 
$
10,016,429
   
$
9,052,886
 

For the three months ended January 31, 2019 and 2018, depreciation expense totaled $315,964 and $320,878, of which $268,664 and $274,270 were included in cost of revenues, respectively, and of which $47,301 and $46,608 were included in general and administrative expenses, respectively. For the nine months ended January 31, 2019 and 2018, depreciation expense totaled $902,237 and $1,054,856, of which $757,941 and $897,938 was included in cost of revenues, respectively, and of which $144,297 and $156,918 were included in general and administrative expenses, respectively. Depreciation is not taken during the period of construction or equipment installation. Upon completion of the installation of manufacturing equipment or any construction in progress, construction in progress balances will be classified to their respective property and equipment category.

- 11 -

NOTE 5 - LAND USE RIGHTS

As of January 31, 2019 and April 30, 2018, land use rights consisted of the following:
 
 
January 31,
2019
 
April 30,
2018
 
 
Estimated Life
(unaudited)
 
 
 
Land use right
45 Years
 
$
2,369,935
 
 
$
2,507,726
 
Less: accumulated amortization
 
 
 
(553,129
)
 
 
(543,120
)
 
  
 
$
1,816,806
 
 
$
1,964,606
 

In conjunction with our acquisition of Qufu Shengwang, we acquired land use rights for properties located in the PRC until March 14, 2054. For the three month periods ended January 31, 2019 and 2018, amortization expense related to land use rights amounted to $12,852 and $13,471, respectively. For the nine month periods ended January 31, 2019 and 2018, amortization expense related to land use rights amounted to $39,207 and $39,736, respectively.
 
NOTE 6 - RELATED PARTY TRANSACTIONS

Accounts receivable - related parties and revenue - related parties

As of January 31, 2019 and April 30, 2018, $2,287,466 and $2,576,944 in accounts receivable - related parties, respectively, were related to sales of products to Qufu Shengwang Import and Export Co., Ltd. ("Qufu Shengwang Import and Export"), a Chinese entity owned by our Chairman, Mr. Laiwang Zhang, and Shangdong Shengwang Pharmaceutical Co., Ltd. ("Pharmaceutical Corporation"), a Chinese entity owned by our Chairman, Mr. Laiwang Zhang. For the three months ended January 31, 2019 and 2018, we recorded revenue - related parties and cost of revenue – related parties of $1,086,794 and $1,591,329, $1,127,662 and $1,605,388, respectively, from Qufu Shengwang Import and Export and Pharmaceutical Corporation. For the nine months ended January 31, 2019 and 2018, we recorded revenue - related parties and cost of revenue – related parties of $ 3,206,484 and $1,858,709, $3,029,909 and $1,878,662, respectively, from Qufu Shengwang Import and Export and Pharmaceutical Corporation.

Due to related parties

From time to time, we receive advances from related parties and advance funds to related parties for working capital purposes. In the nine months ended January 31, 2019 and 2018, we received advances from related parties for working capital totaled $3,946,954 and $5,068,601, respectively, and we repaid to related parties a total of $2,923,479 and $3,251,990, respectively. In the three and nine months ended January 31, 2019 and 2018, interest expense related to due to related parties amounted to $35,855 and $25,945, and $101,546 and $71,135, respectively, which were included in interest expense in the accompanying consolidated statements of operations and comprehensive loss, and in connection with the advances of $743,196 (RMB5,000,000) and $1,189,114 (RMB8,000,000) from Pharmaceutical Corporation. These advances bear interest at the rate of 7.0% and 6.3% per annum, respectively. As of January 31, 2019, the balance we owed Pharmaceutical Corporation, Qufu Shengwang Import and Export and Mr. Weidong Chai, a management member of Qufu Shengren Pharmaceutical Co., Ltd., amounted to $2,947,333, $391,197 and $177,551, respectively. As of April 30, 2018, the balance we owed to Pharmaceutical Corporation, Qufu Shengwang Import and Export, and Mr. Weidong Chai, a management member of Qufu Shengren Pharmaceutical Co., Ltd., amounted to $2,280,266, $103,169 and $175,781, respectively.

As of January 31, 2019 and April 30, 2018, due to (from) related parties activities consisted of the following: 
 
 
 
Shandong Shengwang Pharmaceutical
Co., Ltd.
   
Qufu
Shengwang
Import and Export Co., Ltd.
   
Mr. Wedong Chai
   
Total
 
Balance due to related parties, April 30, 2018
 
$
2,280,266
   
$
103,169
   
$
175,781
   
$
2,559,216
 
Working capital advances from related parties
   
3,521,805
     
413,917
     
11,232
     
3,946,954
 
Repayments
   
(2,793,209
)
   
(130,270
)
   
-
     
(2,923,479
)
Effect of foreign currency exchange
   
(61,529
)
   
4,381
     
(9,462
)
   
(66,610
)
Balance due to related parties, January 31, 2019
 
$
2,947,333
   
$
391,197
   
$
177,551
   
$
3,516,081
 
  
- 12 -

NOTE 7 - PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets as of January 31, 2019 and April 30, 2018 totaled $2,658,517 and $2,284,379, respectively. As of January 31, 2019, prepaid expenses and other current assets includes $2,283,922 prepayments to suppliers for merchandise that had not been shipped to us and services that had not been provided to us and $374,595 for business related employees' advances. As of April 30, 2018, prepaid expenses and other current assets includes $1,366,280 prepayments to suppliers for merchandise that had not been shipped to us and services that had not been provided to us, $715,553 prepayment for employees' stock-based compensation and $202,546 for business related employees' advances.

On December 1, 2015, we entered into three year employment agreements with four employees. Pursuant to employment agreements, we issued a total of 23 million shares of the Company's common stock to them, valued at $3,680,000, as employees' stock-based compensations over three-year term of their employment from December 1, 2015 through November 30, 2018. We will amortize these compensations over three years from December 1, 2015 to November 30, 2018 and we recognized $715,553, $1,226,668, $1,226,669 and $511,110 as stock-based compensation expenses during the nine months of fiscal year 2019, fiscal year 2018, fiscal year 2017 and fiscal year 2016, respectively. We have not recorded any more stock-based compensation as prepaid compensation as of January 31, 2019.

During the third quarter of fiscal 2013, Qufu Shengwang paid Qufu Public Auction Center (the "Center") $610,751 as deposit for renewing the land use right. The deposit is required for the Center to appraise the land use right, which we do not know when we can receive the remaining refund. We received a total refund of $465,904 as of January 31, 2019 and the remaining balance of $145,370 and $153,720 has been classified to other long-term asset as of January 31, 2019 and April 30, 2018, respectively.
  
NOTE 8 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses included the following as of January 31, 2019 and April 30, 2018:

Account
 
January 31,
2019
   
April 30,
2018
 
 
 
(unaudited)
       
Accounts payable
 
$
6,555,872
   
$
9,169,871
 
Advanced from customers
   
13,640
     
44,488
 
Accrued salary payable
   
164,363
     
169,321
 
Tax payable
   
119,701
     
199,644
 
Deferred revenue
   
37,821
     
39,994
 
Other payable*
   
2,811,770
     
2,036,686
 
Total accounts payable and accrued expenses
 
$
9,703,167
   
$
11,660,004
 
 
* As of January 31, 2019, other payables consists of general liability, worker's compensation, and medical insurance payable of $589,177, consulting fee payable of $480,472, union and education fees payable of $288,368, interest payables for individual loans of $624,756, advances from employees of $366,199 and other miscellaneous payables of $462,798. As of April 30, 2018, other payables consists of general liability, worker's compensation, and medical insurance payable of $558,789, consulting fee payable of $312,782, union and education fees payable of $304,930, interest payables for short-term loans of $384,356, advances from employees of $210,115 and other miscellaneous payables of $265,714. 

NOTE 9 - LOAN PAYABLE

Short-term loan payable

Short-term loans are obtained from various individual lenders that are due within one year for working capital purpose. These loans are unsecured and can be renewed with 10 days advance notice prior to maturity date. As of January 31, 2019 and April 30, 2018, short-term loans consisted of the following:

- 13 -


 
 
January 31,
2019
   
April 30,
2018
 
 
 
(Unaudited)
       
Loan from Min Wu, an employee of Qufu Shengren, due on October 5, 2019, with an annual interest rate of 10%, renewed at October 6, 2018.
 
$
32,819
   
$
34,704
 
Loan from Jianjun Yan, non-related individual, due on October 6, 2019, with an annual interest rate of 10%, renewed at October 7, 2018 and accrued interest enrolled into debt principal of RMB880,880 ($131,482).
   
1,445,466
     
1,389,531
 
Loan from Jianjun Yan, non-related individual, due on March 31, 2019, with annual interest rate of 4%, renewed at April 1, 2018.
   
1,169,538
     
1,236,710
 
Loans from Jianjun Yan, non-related individual, due on demand, with free interest at January 27, 2018.
   
-
     
457,457
 
Loan from Junzhen Zhang, non-related individual, due on October 5, 2019, with an annual interest rate of 10%, renewed at October 6, 2018.
   
23,868
     
25,239
 
Loan from Jian Chen, non-related individual, due on January 26, 2020 and April 10, 2019, bearing an annual interest rate of 10%, with the principle amount of RMB847,000 ($126,352) and RMB330,000 ($49,228) at January 27, 2019 and April 11, 2018, respectively.
   
175,580
     
173,518
 
Loan from Qing Kong, non-related individual, due on March 6, 2019, with an annual interest rate of 10% at March 7, 2018, See Note 12.
   
72,201
     
76,348
 
Loan from Qing Kong, non-related individual, due on January 8, 2020, with an annual interest rate of 10% at January 9, 2019.
   
32,819
     
31,549
 
Loan from Guihai Chen, non-related individual, due on March 10, 2020, with an annual interest rate of 10% at March 11, 2019, See Note 12.
   
17,901
     
18,929
 
Loan from Guihai Chen, non-related individual, due on September 20, 2019, with an annual interest rate of 10%, renewed at September 21, 2018.
   
29,835
     
31,549
 
Loan Weifeng Kong, non-related individual, due on November 28, 2018, with an annual interest rate of 10% at November 29, 2017.
   
29,835
     
31,549
 
Loan Shidong Wang, non-related individual, due on March 7, 2019, with an annual interest rate of 4% at March 8, 2018, See Note 12.
   
1,551,428
     
1,640,534
 
Loan from Xuxu Gu, non-related individual, due on March 8, 2019, with an annual interest rate of 4%, renewed at March 9, 2018, See Note 12.
   
1,491,758
     
1,577,436
 
Loan from Dadong Mei, non-related individual, due on March 8, 2019, with an annual interest rate of 4%, renewed at March 9, 2018, See Note 12.
   
1,491,758
     
1,577,436
 
Loan Xuxu Gu, non-related individual, due on September 27, 2019, with an annual interest rate of 4% at September 28, 2017.
   
1,596,182
     
-
 
Total
 
$
9,160,988
   
$
8,302,489
 
 
  Long-term loan payable
Long-term loans are payable obtained from various individual lenders that are due more than one year for working capital purpose. These loans are unsecured and can be renewed with one month advance notice prior to maturity date. As of January 31, 2019 and April 30, 2018, long-term loans consisted of the following:

- 14 -


 
 
January 31,
2019
   
April 30,
2018
 
 
 
(Unaudited)
       
Loan Xuxu Gu, non-related individual, due on September 27, 2019, with an annual interest rate of 4% at September 28, 2017. (Reclassified from long-term loan to short-term loan on September 28, 2018)
 
$
-
   
$
1,687,857
 
Loan Xuxu Gu, non-related individual, due on July 13, 2020, with an annual interest rate of 4% at July 14, 2018.
   
432,610
     
-
 
Loan Xuxu Gu, non-related individual, due on August 15, 2020, with an annual interest rate of 4% at August 16, 2018.
   
507,198
     
-
 
Loan Mingbang Ma, non-related individual, due on May 22, 2020, with an annual interest rate of 4% at May 23, 2018.
   
298,352
     
-
 
Loan Weiwei Lian, non-related individual, due on May 29, 2020, with an annual interest rate of 4% at May 30, 2018.
   
1,491,758
     
-
 
Loan Guanghua Xia, non-related individual, due on June 8, 2020, with an annual interest rate of 4% at June 9, 2018.
   
1,342,582
     
-
 
Loan Guanghua Xia, non-related individual, due on December 31, 2020, with an annual interest rate of 4% at January 1, 2019.
   
417,692
     
-
 
Loan Yuehu Zhou, non-related individual, due on June 12, 2020, with an annual interest rate of 4% at June 13, 2018.
   
1,342,582
     
-
 
Total:
 
$
5,832,774
   
$
1,687,857
 
 
For the three and nine months ended January 31, 2019 and 2018, interest expense related to short-term loans and long-term loans amounted to $171,705 and $126,138, and $488,641 and $316,578, respectively, which were included in interest expense in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss.
 
NOTE 10 - SEGMENT INFORMATION

The following information is presented in accordance with ASC Topic 280, "Segment Reporting", for the three and nine months ended January 31, 2019 and 2018; we accounted for three reportable business segments - (1) natural sweetener (stevioside), (2) traditional Chinese medicines and (3) corporate and other. Our reportable segments are strategic business units that offer different products and are managed separately based on the fundamental differences in their operations. Condensed financial information with respect to these reportable business segments for the three and nine months ended January 31, 2019 and 2018 is as follows:
 
 
 
Three Months Ended January 31,
   
Nine Months Ended January 31,
 
 
 
2019
   
2018
   
2019
   
2018
 
Revenues:
                       
Chinese medicine - third parties
 
$
713,905
   
$
675,927
   
$
2,020,026
   
$
2,099,147
 
Chinese medicine - related parties
   
5,416
     
-
     
11,369
     
-
 
Total Chinese medicine
   
719,321
     
675,927
     
2,031,395
     
2,099,147
 
 
                               
Stevioside - third parties
   
4,567,310
     
4,058,336
     
12,336,433
     
11,135,229
 
Stevioside - related parties
   
1,081,378
     
1,591,329
     
3,195,115
     
1,858,709
 
Total Stevioside
   
5,648,688
     
5,649,665
     
15,531,548
     
12,993,938
 
Total segment and consolidated revenues
 
$
6,368,009
   
$
6,325,592
   
$
17,562,943
   
$
15,093,085
 

- 15 -


 
 
Three Months Ended January 31,
   
Nine Months Ended January 31,
 
 
 
2019
   
2018
   
2019
   
2018
 
Interest (expense) income:
                       
Chinese medicine
 
$
266
   
$
386
   
$
995
   
$
742
 
Stevioside
   
(207,474
)
   
(152,055
)
   
(589,969
)
   
(387,670
)
Total segment and consolidated interest expense
 
$
(207,208
)
 
$
(151,669
)
 
$
(588,974
)
 
$
(386,928
)
Depreciation and amortization:
                               
Chinese medicine
 
$
47,431
   
$
33,531
   
$
117,085
   
$
170,961
 
Stevioside
   
281,385
     
300,818
     
824,359
     
1,032,021
 
Total segment and consolidated depreciation and amortization
 
$
328,816
   
$
334,349
   
$
941,444
   
$
1,202,982
 
Loss before income taxes:
                               
Chinese medicine
 
$
(5,879
)
 
$
(6,964
)
 
$
(122,686
)
 
$
(521,873
)
Stevioside
   
(902,153
)
   
(551,179
)
   
(2,390,017
)
   
(2,278,166
)
Corporate and other
   
(110,698
)
   
(314,667
)
   
(801,707
)
   
(1,021,871
)
Total consolidated loss before income taxes
 
$
(1,018,730
)
 
$
(872,810
)
 
$
(3,314,410
)
 
$
(3,821,910
)
 
 
 
January 31,
2019
   
April 30,
2018
 
Segment property and equipment:
           
  Chinese medicine
 
$
1,049,498
   
$
1,129,884
 
  Stevioside
   
8,966,931
     
7,923,002
 
  Corporate and other
   
-
     
-
 
    Total consolidated assets
 
$
10,016,429
   
$
9,052,886
 
 
NOTE 11 - CONCENTRATIONS
 
(i)    Customer Concentrations
 
For the three months ended January 31, 2019 and 2018, customers accounting for 10% or more of the Company's revenue were as follows:
 
 
Net Sales
 
 
For the three months ended
January 31, 2019
 
For the three months ended
January 31, 2018
 
 
Chinese Medicine
 
Stevioside
 
Chinese Medicine
 
Stevioside
 
Qufu Shengwang Import and Export Trade Co., Ltd(1)
   
-
     
17.0
%
   
-
     
25.2
%
Shandong YidaTong Enterprise Co., Ltd
   
-
     
*
     
-
     
16.5
%
Total
   
-
     
17.0
%
   
-
     
41.7
%

 For the nine months ended January 31, 2019 and 2018, customers accounting for 10% or more of the Company's revenue were as follows: 

 
Net Sales
 
 
For the nine months ended
January 31, 2019
 
For the nine months ended
January 31, 2018
 
 
Chinese Medicine
 
Stevioside
 
Chinese Medicine
 
Stevioside
 
Qufu Shengwang Import and Export Trade Co., Ltd (1)
   
-
     
18.2
%
   
-
     
12.3
%
Shandong YidaTong Enterprise Co., Ltd
   
-
     
*
     
-
     
10.6
%
Total
   
-
     
18.2
%
   
-
     
22.9
%
 
(1)  Qufu Shengwang Import and Export Co., Ltd is a related party, an entity owned by Mr. Laiwang Zhang.
 *   This represents less than 10% of the Company's revenue for the three and nine months ended January 31, 2018.
- 16 -


(ii)    Vendor Concentrations

For the three months ended January 31, 2019 and 2018, suppliers accounting for 10% or more of the Company's purchases were as follows:

 
Net Purchases
 
 
For the three months ended
January 31, 2019
 
For the three months ended
January 31, 2018
 
 
Chinese Medicine
 
Stevioside
 
Chinese Medicine
 
Stevioside
 
Dongtai Jintudi Stevia Co., Ltd.
   
-
     
-
     
-
     
11.3
%
Zhucheng Haotian Pharmaceutical Co., Ltd.
   
-
     
27.4
%
   
-
     
*
 
Dongtai Zhongxin Stevia Corp.
   
-
     
18.1
%
   
-
     
-
 
Total
   
-
     
45.5
%
   
-
     
11.3
%

For the nine months ended January 31, 2019 and 2018, suppliers accounting for 10% or more of the Company's purchases were as follows:

 
Net Purchases
 
 
For the nine months ended
January 31, 2019
 
For the nine months ended
January 31, 2018
 
 
Chinese Medicine
 
Stevioside
 
Chinese Medicine
 
Stevioside
 
Dongtai Jintudi Stevia Co., Ltd
   
-
     
*
     
-
     
14.7
%
Dongtai Yandun Stevia Corp.
   
-
     
*
     
-
     
12.7
%
Zhucheng Haotian Pharmaceutical Co., Ltd.
   
-
     
14.9
%
   
-
     
-
 
Dongtai Zhongxin Stevia Corp.
   
-
     
31.6
%
   
-
     
-
 
Total
   
-
     
46.5
%
   
-
     
27.4
%

*  This represents less than 10% of the Company's purchases for the three and nine months ended January 31, 2019.
 
NOTE 12 - SUBSEQUENT EVENTS
 
  On March 7, 2019, we renewed the loan from Qing Kong, non-related individual, for the totally amount of RMB532,400 ($79,421), consisted of previous loan's principal amount of RMB484,000 ($72,201) and accrued interest of RMB48,400 ($7,220), with an annual interest rate of 10% and new due date of March 6, 2020.

On March 10, 2019, we renewed the loan from Guihai Chen, non-related individual, for the totally amount of RMB132,000 ($19,691), consisted of previous loan's principal amount of RMB120,000 ($17,901) and accrued interest of RMB12,000 ($1,790), with an annual interest rate of 10% and new due date on March 9, 2020.

On March 9, 2019, we renewed the loan from Shidong Wang, non-related individual, for the totally amount of RMB10,816,000 ($1,613,485), consisted of previous loan's principal amount of RMB10,400,000 ($1,551,428) and accrued interest of RMB416,000 ($62,057), with an annual interest rate of 4% and new due date on March 8, 2020.

On March 9, 2019, we renewed the loan from Xuxu Gu, non-related individual, for the totally amount of RMB10,800,000 ($1,611,099), consisted of previous loan's principal amount of RMB10,000,000 ($1,491,758) and accrued interest of RMB800,000 ($119,341), with an annual interest rate of 4% and new due date on March 8, 2021.

On March 9, 2019, we renewed the loan from Dadong Mei, non-related individual, for the totally amount of RMB10,800,000 ($1,611,099), consisted of previous loan's principal amount of RMB10,000,000 ($1,491,758) and accrued interest of RMB800,000 ($119,341), with an annual interest rate of 4% and new due date on March 8, 2021.


- 17 -
 
ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with the information contained in the preceding unaudited condensed consolidated financial statements and footnotes and our 2018 Annual Report on Form 10-K for fiscal year ended April 30, 2018.

OVERVIEW
 
We sell stevioside, a natural sweetener, as well as herbs used in traditional Chinese medicines. Substantially all of our operations are located in the PRC. We have built an integrated company with the production and distribution capabilities designed to meet the needs of our customers.
 
Our operations were organized in two operating segments related to our product lines:
 
 
-
 
Stevioside, and
 
-
 
Chinese Medicine.
 
Going Concern

The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has a significant accumulated deficit and incurred recurring losses. The Company's cash balance and revenues generated are not currently sufficient and cannot be projected to cover operating expenses for the next twelve months from the date of this report. These factors raise doubt as to the ability of the Company to continue as a going concern. Management's plans include attempting to improve its business profitability, its ability to generate sufficient cash flow from its operations to meet its operating needs on a timely basis, obtain additional working capital funds through debt and equity financings, and restructure on-going operations to eliminate inefficiencies to raise cash balance in order to meet its anticipated cash requirements for the next twelve months from the date of this report. Management intends to make every effort to improve its current sales forecast to further develop and expand the international markets for its new products as well as continuing with the current sources of funds to meet working capitals needs on as needed basis.  There can be no assurance that these plans and arrangements will be successful.
 
The ability of the Company to continue as a going concern is dependent upon its ability to achieve profitable operations and raise additional capital. The accompanying unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amount or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.
 
Recent Developments

Sunwin Stevia has approximately 1,200 metric tons of manufacturing capacity per year to produce high-grade stevia extract. With these manufacturing facilities, Sunwin Stevia is able to deliver stevia products containing Rebaudioside A in a range of 50% to 99% with a format of powder, granular, or tablet.

We also set up a new product line for Metformin, the raw material of Metformin hydrochloride tablets. Metformin is the first-line medication for the treatment of type 2 diabetes, particularly in people who are not satisfied with simple diet control, especially those with obesity and hyperinsulinemia. This drug not only has hypoglycemic effect, but also may have the effect of reducing body weight and hyperinsulinemia. It can be effective in patients with poor efficacy of certain sulfonylureas, such as sulfonylureas, intestinal glycosidase inhibitors or thiazolidinedione hypoglycemic agents, which are more effective than single use. It can also be used in patients with insulin therapy to reduce insulin consumption.

In fiscal 2018 and the first nine months of fiscal 2019, we have invested approximately $1,019,000 and $716,000, respectively, in this new facility. The new manufacturing facility is fully equipped with stainless steel equipment without any plastic while it has a fully automated system in order to prevent any potential contamination from operators and plastic. In addition, the new manufacturing facility uses the most advanced production equipment that is the first being used for our production in the industry, such as the scraper with centrifuge and fluidized drying system.

Stevioside Segment

Stevioside and rebaudioside are all natural low calorie sweeteners extracted from the leaves of the stevia rebaudiana plant. Stevioside is a safe and natural alternative to sugar for people needing low sugar or low calorie diets. Stevioside can be used to replace sugar in beverages and foods, including those that require baking or cooking where synthetic chemical based sweetener replacements are not suitable.
- 18 -
 
Steviosin is a natural low calorie stevioside extract for medicinal use, containing rebaudioside A at 90% with the total steviol glycosides meeting or exceeding 95% on a dry weight basis. Steviosin is used as an alternative sweetener in pharmaceutical production in China.

OnlySweet is an all natural, zero calorie, dietary supplement comprised of three natural ingredients, including stevioside.  Based on our strategy to develop new products that contain our stevia products, we are evaluating our strategy for the sale and distribution of OnlySweet.

In an effort to meet the international food safety standards mandated by larger consumer product companies that we expect to target as customers in the future, we have made capital investments to enhance our manufacturing facilities, equipment and documentation systems, changed certain manufacturing processes and carried out additional personnel training in order to meet these standards.  These investments allowed us to meet the HACCP System Certification, ISO 9001:2015 Certification and ISO 22000:2005 Food Safety Certification. We obtained these certifications in October 2015.

Chinese Medicine Segment

In our Chinese medicine segment, we manufacture and sell approximately 190 different extracts, which can be divided into the following three general categories:

 
-
 
single traditional Chinese medicine extracts;
 
-
 
compound traditional Chinese medicine extracts; and
 
-
 
purified extracts, including active parts and monomer compounds such as soy isoflavone.
 
We have evaluated alternatives as to the potential disposition of the Chinese medicine segment to further streamline our product offering and focus our business on producing and selling high-quality stevia products. The exit strategy contemplated for the Chinese medicine segment has also been influenced by our concerns regarding the profitability of this segment in the near future. The competition in the Chinese medicine market has strengthened over the past few months. In addition, the Chinese government continues to issue more regulations covering the supply of Chinese herbal raw materials and has increased the regulatory manufacturing standards on this segment. These measures are expected to further increase our raw materials and production costs in the coming quarters and beyond. However, this segment is currently operating at full capacity and we do not expect significant growth potential from this segment in the near future.  

OUR PERFORMANCE
 
 Our revenues totaled approximately $6,368,000 during the three months ended January 31, 2019, an increase of 0.7%, as compared with the same period in 2018, and our gross margin increased to 14.9% from 11.6%. Our total operating expenses in the three months ended January 31, 2019 increased by approximately $113,000, or 6.8% compared to the same period in 2018 primarily due to an increase of approximately $35,000, or 12.4% in research and development expenses and an  increase of approximately $129,000, or 21.8% in selling expense, offset by a decrease of approximately $2,000, or 100.0% in loss on disposition of property and equipment,  and a decrease of approximately $50,000, or 6.4% in general and administrative expense. Our net loss for the three months ended January 31, 2019 was approximately $1,019,000, compared to $873,000 in the same period in 2018.

Our revenues totaled $17,563,000 during the nine months ended January 31, 2019, an increase of 16.4% as compared with the same period in 2018, while our gross margin increased to 12.1% from 8.7%. Our total operating expenses in the nine months ended January 31, 2019 decreased by approximately $55,000 or 1.1% compared to the same period in 2018, primarily due to a decrease of approximately $246,000 or 9.8% in general and administrative expense, and a decrease of approximately $285,000, or 100% in loss on disposition of property and equipment, offset by an increase of $424,000 and $52,000, or 29.3% and 8.0% in selling expense and research and development, respectively. Our net loss for the nine months ended January 31, 2019 was approximately $3,314,000, a decrease of approximately $508,000, compared to the $3,822,000 in the same period in 2018.

Our operating performance for the three months ended January 31, 2019 was primarily driven by an increase of 6.4% from our sales in Chinese medicine segment and 12.5% increase from our stevia products in sales to the third party offset by a decrease of 32.0% from our stevia products in sales to the related parties. The sales to related parties for international customers accounted for 17.1% of our total stevioside sales in the three months ended January 31, 2019. Our operating performance for the nine months ended January 31, 2019 was primarily driven by an increase of 19.5% from our stevia products in sales revenue in our Stevioside segment offset by a decrease of 3.2% in sales revenue from our Chinese medicine segment. The sales to related parties for international customers accounted for 20.6% of our total stevioside sales in the nine months ended January 31, 2019. 
- 19 -
 
While we have broadened our stevia product offerings to include a number of higher quality stevia grades needed in new product formulations we are developing to introduce to the U.S. and European food and beverage industry, the demand for higher grade stevia products has yet to materialize to the degree we had anticipated, and we hope that our sales volume in higher grade stevia products will increase in fiscal 2019 as the demands increase. Stevia has became more widely accepted by the food industry and many new stevia manufacturers have entered this industry in the past few years, and recently we introduced a new product line. We are now focusing on new types of stevia products, including tablets, liquid, High A products, and others. We expect to consistently increase our sales of our new products; however we cannot quantify this increase and its effects on future periods.

Our Outlook

We believe that there are significant opportunities for worldwide growth in our Stevioside segment, primarily in the U.S. and EU. For fiscal 2019 and beyond, we will continue to focus on our core business of producing and selling stevioside series products.

Some of the recent favorable observations related to the stevia markets in fiscal 2019 include:

-
Chinese domestic food and beverages, particularly herbal tea manufacturers and the pharmaceutical industry, have increased the use of steviosides;

-
Southeast and South Asia have renewed and increased their interest in stevia, particularly high grade stevia; and

-
The marketing strategy to differentiate ourselves as a producer of higher quality stevia grades and product formulations through these collaboration efforts may lead to sustainable growth in stevia sales volume in the future.

Meanwhile, we are also facing challenges in competitive pricing and raw materials for fiscal 2019. During fiscal 2018, the market prices of stevioside products were impacted by strong price competition among Chinese manufacturers. We expect the pressure from pricing competition to continue in fiscal 2019. We anticipate the price of stevia leaves, the raw material used to produce our stevioside series products, to continue its increase in fiscal 2019.

RESULTS OF OPERATIONS

The following table summarizes our results from operations for the three month periods ended January 31, 2019 and 2018. The percentages represent each line item as a percent of revenues: 

For the Three Months ended January 31, 2019
 
 
 
Chinese Medicine
   
Stevioside
   
Corporate and other
   
Consolidated
 
Total revenues
 
$
719,321
     
100.0
%
 
$
5,648,688
     
100.0
%
 
$
-
   
$
6,368,009
     
100.0
%
Cost of revenues
   
539,455
     
75.0
%
   
4,879,114
     
86.4
%
   
-
     
5,418,569
     
85.1
%
Gross profit
   
179,866
     
25.0
%
   
769,574
     
13.6
%
   
-
     
949,440
     
14.9
%
Research and development expenses
   
1,871
     
0.3
%
   
317,876
     
5.6
%
   
-
     
319,747
     
5.0
%
Other operating expenses
   
184,578
     
25.7
%
   
1,150,685
     
20.4
%
   
110,698
     
1,445,961
     
22.7
%
Other income (expenses)
   
703
     
0.1
%
   
(203,165
)
   
(3.6
)%
   
-
     
(202,462
)
   
(3.2
)%
Loss before income taxes
 
$
(5,879
)
   
(0.8
)%
 
$
(902,153
)
   
(16.0
)%
 
$
(110,698
)
 
$
(1,018,730
)
   
(16.0
)%

- 20 -


For the Three Months ended January 31, 2018
 
 
 
Chinese Medicine
   
Stevioside
   
Corporate and other
   
Consolidated
 
Total revenues
 
$
675,927
     
100.0
%
 
$
5,649,665
     
100.0
%
 
$
-
   
$
6,325,592
     
100.0
%
Cost of revenues
   
531,693
     
78.7
%
   
5,057,083
     
89.5
%
   
-
     
5,588,776
     
88.3
%
Gross profit
   
144,234
     
21.3
%
   
592,582
     
10.5
%
   
-
     
736,816
     
11.7
%
Loss on disposition of property and equipment
   
2,164
     
0.3
%
   
266
     
0.0
%
   
-
     
2,430
     
0.0
%
Research and development expenses
   
1,387
     
0.2
%
   
282,964
     
5.0
%
   
-
     
284,351
     
4.5
%
Other operating expenses
   
189,427
     
28.0
%
   
862,335
     
15.3
%
   
314,667
     
1,366,429
     
21.6
%
Other income
   
41,779
     
6.2
%
   
1,805
     
0.0
%
   
-
     
43,584
     
0.7
%
Loss before income taxes
 
$
(6,964
)
   
(1.0
)%
 
$
(551,179
)
   
(9.8
)%
 
$
(314,667
)
 
$
(872,810
)
   
(13.8
)%

The following table summarizes our results from operations for the nine month periods ended January 31, 2019 and 2018.
 
For the Nine Months ended January 31, 2019
 
 
 
Chinese Medicine
   
Stevioside
   
Corporate and other
   
Consolidated
 
Total revenues
 
$
2,031,395
     
100.0
%
 
$
15,531,548
     
100.0
%
 
$
-
   
$
17,562,943
     
100.0
%
Cost of revenues
   
1,618,822
     
79.7
%
   
13,818,210
     
89.0
%
   
-
     
15,437,032
     
87.9
%
Gross profit
   
412,573
     
20.3
%
   
1,713,338
     
11.0
%
   
-
     
2,125,911
     
12.1
%
Research and development expenses
   
3,350
     
0.2
%
   
699,533
     
4.5
%
   
-
     
702,883
     
4.0
%
Other operating expenses
   
534,809
     
26.3
%
   
2,803,532
     
18.1
%
   
801,707
     
4,140,048
     
23.6
%
Other income (expenses)
   
2,900
     
0.1
%
   
(600,290
)
   
(3.9
)%
   
-
     
(597,390
)
   
(3.4
)%
Loss before income taxes
 
$
(122,686
)
   
(6.0
)%
 
$
(2,390,017
)
   
(15.4
)%
 
$
(801,707
)
 
$
(3,314,410
)
   
(18.9
)%

For the Nine Months ended January 31, 2018
 
 
 
Chinese Medicine
   
Stevioside
   
Corporate and other
   
Consolidated
 
Total revenues
 
$
2,099,147
     
100.0
%
 
$
12,993,938
     
100.0
%
 
$
-
   
$
15,093,085
     
100.0
%
Cost of revenues
   
1,720,361
     
82.0
%
   
12,067,132
     
92.9
%
   
-
     
13,787,493
     
91.3
%
Gross profit
   
378,786
     
18.0
%
   
926,806
     
7.1
%
   
-
     
1,305,592
     
8.7
%
Loss on disposition of property and equipment
   
253,890
     
12.1
%
   
31,260
     
0.2
%
           
285,150
     
1.9
%
Research and development expenses
   
2,330
     
0.1
%
   
648,324
     
5.0
%
   
-
     
650,654
     
4.3
%
Other operating expenses
   
560,326
     
26.7
%
   
2,379,479
     
18.3
%
   
1,021,871
     
3,961,676
     
26.3
%
Other expenses
   
(84,113
)
   
(4.0
)%
   
(145,909
)
   
(1.1
)%
   
-
     
(230,022
)
   
(1.5
)%
Loss before income taxes
 
$
(521,873
)
   
(24.9
)%
 
$
(2,278,166
)
   
(17.5
)%
 
$
(1,021,871
)
 
$
(3,821,910
)
   
(25.3
)%

 
- 21 -
 
Revenues

Total revenues in the three months ended January 31, 2019 increased by approximately 0.7%, as compared to the same period in 2018. Stevioside revenues, which accounted for 88.7% and 89.3% of our total revenues in the three months ended January 31, 2019 and 2018, respectively, decreased by only $977 or 0.02%, while Chinese medicine revenues increased by approximately $43,000 or 6.4%.

Within our Stevioside segment, revenues from sales to third parties increased by 12.5% while sales to the related parties decreased by 32.0% in the three months ended January 31, 2019, as compared to the same period in 2018, primarily due to an increasing demand from the domestic market and the results of our effort to increase sales. We have been trying to develop our domestic market in this fiscal year. Since we do not have the authorization to export products from China, we outsourced all of our exporting business to a related party, Qufu Shengwang Import and Export, which has authorizations to export. We started to outsource our exporting business to Yi-Da Tong, which is a third party export agent since March 2016. Revenues from the sales in the third parties increased from 74.8% to 82.9% of our total revenue in the three months ended January 31, 2019, as compared to the same period in 2018. While the adoption rate for stevia in the food and beverage sector has been slower than expected, we sold 151 metric tons and 140 metric tons of stevioside for the three months ended January 31, 2019 and 2018, respectively. Our low grade stevia products, Stevioside and A3-97, accounted for approximately 23.9% and 21.9% of our total Stevioside segment revenue in the three months ended January 31, 2019.

Total revenues in the nine months ended January 31, 2019 increased by 16.4% as compared to the same period in 2018.  Stevioside revenues, which accounts for 88.4% and 86.1% of our total revenues in the nine months ended January 31, 2019 and 2018, respectively, increased by 19.5%, while Chinese medicine revenues decreased by approximately $68,000 or 3.2%. During the nine months ended January 31, 2019, within our Stevioside segment, our sales volume increases to approximately 390 metric tons, a 11.9% increase; the average unit price of our stevia products was decreased by 5.0% as to stay ahead of competition and to gain market share, as compared to the same period in 2018. Stevioside revenues from sales to third parties increased by 10.8% and sales to the related parties increased by 71.9% in the nine months ended January 31, 2019, as compared to the same period in 2018. We generated approximately $1,495,000 and $1,229,000 in revenue from producing over 23.0 metric tons and 16.4 metric tons of A3-99 and A3-98 in the nine months ended January 31, 2019 and 2018, respectively. The revenue of the customized orders for restructuring by enzyme based on our Stevioside products accounted approximately $1,425,000 in the nine months ended by January 31, 2019, increased by 28.9%, as compared to the same period in 2018. We also generated revenue from the sale of our new products that were developed in this year. The sales of Metformin in Stevioside segment was approximately 133 metric tons and 467 metric tons, $634,000 and $2,082,000 in the three and nine months ended January 31, 2019, respectively.

The sales in Chinese Medicine segment approximately 265.9 metric tons for the nine months ended January 31, 2019, which decreased by 8.8%, as compared to the same period in 2018, while sales amount decreased by 3.2%. We have more than 225 products in the Chinese Medicine segment, and their prices fluctuate depending on the market. We expect demand to increase in the future as we expand our client base, however, we are not able to quantify this future increase.

Our unit sale price of stevioside series products fluctuated from month to month in the three and nine months ended January 31, 2019, which was mainly affected by the market environment; the average unit sale price decreased by approximately 11.9% and 5.0% compared to the same period in 2018, respectively. Facing challenges due to competitive pricing and difficulties sourcing raw materials for fiscal year 2019, the market prices of stevioside, products were impacted by strong price competition among Chinese manufacturers. We anticipate the price of stevia leaves, the raw material we use to produce our stevioside series products, will continue to increase in the near future based on data available to us and we purchase stevia leaves in bulk.
 
Cost of Revenues and Gross Margin

Cost of revenues in the three months ended January 31, 2019 decreased by 22.0%, compared to the same period in 2018, reflecting the lower cost of sales to related party. Cost of revenues in the nine months ended January 31, 2019 increased by 65.5%, compared to the same period in 2018, reflecting the higher total revenue in this period of 2019. Cost of revenues as a percentage of revenues decreased from 88.4% to 85.1%, and 91.3% to 87.9%, during the three and nine months ended January 31, 2019 and 2018, respectively. 

Our consolidated gross margin for the three months ended January 31, 2019 was 14.9%, as compared to 11.6% in the same period in 2018.  The consolidated gross margin for the nine months ended January 31, 2019 increased to 12.1%, compared to 8.7% for the same period in 2018. Gross margin in Stevioside segment increased from10.5% to 13.6%, and 7.1% to 11.0%, for the three and nine months ended January 31, 2019, comparing the same period in 2018, respectively, which was primarily due to the improvements in efficiency of our production line to offset the higher raw material costs.
- 22 -
 
Gross margin in Chinese Medicine segment increased from 21.3% to 25.0%, and from 18.0% to 20.3% in the three and nine months ended January 31, 2019, compared to the same period in 2018, respectively. We believe that the slower market movement for Chinese veterinary medicines seen in prior periods has stabilized and the market has improved. Since we purchase our raw materials on the spot market, we are unable to predict, with any degree of certainty, our raw material costs and their impact on our gross margin in future periods. 

Selling Expenses

For the three months ended January 31, 2019, we had an increase of approximately $129,000, or 21.8% in selling expenses, as compared to the same period in 2018. The increase was primarily due to the approximately $169,000 increase in advertising, $13,000 increase in salary and wages, $5,000 increase in office expense and $5,000 increase in miscellaneous expense, offset by approximately $43,000 decrease in promotion expense, $11,000 decrease in commission and $9,000 decrease in shipping and freight in the three months ended January 31, 2019.

For the nine months ended January 31, 2019, we had an increase of approximately $424,000, or 29.3% in selling expenses, as compared to the same period in 2018. The increase was primarily due to the increase of approximately $120,000 in promotion and marketing expenses, $181,000 increase in advertising expenses, $74,000 increase in office expense, $50,000 increase in US warehouse expense, $16,000 increase in travel and entertainment expenses and $13,000 increase in local tax for sales related, offset by a decrease of $8,000 in salary and wage, $13,000 decrease in commission and $9,000 decrease in shipping and freight in the nine months ended January 31, 2019.

General and Administrative Expenses
 
Our general and administrative expenses for the three months ended January 31, 2019 decreased by approximately $50,000, or 6.4% from the same period in 2018. The decrease was primarily due to a decrease of approximately $204,000 in employees' stock base compensation, $15,000 decrease in depreciation and amortization expenses, $12,000 decrease in consulting and service expense, $6,000 decrease in travel, meals and entertainment expenses and $34,000 decrease in office expense, offset by $81,000 increase in salary and wage expenses, $13,000 increase in repairs and maintenance fee, $3,000 increase in telephone fee, $16,000 increase in auto expense, an increase of $14,000 in insurance expense, $44,000 increase in marketing expense, $39,000 increase in bad debt expense and $11,000 increase in miscellaneous expense in three months ended January 31, 2019.
 
Total general and administrative expenses for the nine months ended January 31, 2019 decreased by approximately $246,000, or 9.8% from the comparable period in 2018. The decrease was primarily due to approximately $204,000 in employees' stock base compensation,  $148,000 decrease in depreciation and amortization expenses, $91,000 decrease in repairs and maintenance fee since the disposition of property and equipment at the end of fiscal year 2018, $15,000 decrease in auto expense, $64,000 decrease in other tax expense and $23,000 decrease in travel, meals and entertainment expenses, offset by an increase of $50,000 in insurance expense, $142,000 increase in marketing expense, $15,000 increase in office expense, $18,000 increase in product testing expense, $69,000 increase in salary and wage expenses and $5,000 increase in miscellaneous expense in the nine months ended January 31, 2019.

Research and Development Expense

For the three months ended January 31, 2019, our research and development expenses amounted to approximately $320,000, as compared to $284,000 for the same period in 2018. The increase of $35,000 was primarily due to more spending on the cost of materials for research and development in the three months ended January 31, 2019. For the nine months ended January 31, 2019, our research and development expenses amounted to approximately $703,000, as compared to $651,000 for the same period in 2018. The increase of $52,000 was primarily due to the increase in spending for third party technical consulting fees in the nine months ended January 31, 2019.

  Other Income (Expenses)

For the three months ended January 31, 2019, other expense, net of other income, amounted to approximately $202,000, an increase of $246,000 as compared to the other income, net of other expense, amounted to approximately $44,000 for the three months ended January 31, 2018. The increase of other expenses was primarily attributable to an increase of other expense of approximately $190,000, an increase of interest expense – related parties of approximately $10,000, and an increase in interest expense in the increased amount of approximately $46,000.

For the nine months ended January 31, 2019, other expense, net of other income, amounted to approximately $597,000, an increase of $367,000 as compared to the other expense, net of other income, amounted to approximately $230,000 for the nine months ended January 31, 2018. The increase was primarily attributable to an increase of interest expense – related parties of approximately $30,000, an increase of interest expense of $172,000, and other expense in the increased amount of approximately $165,000.
- 23 -


Net Loss

Net loss for the three and nine months ended January 31, 2019 was approximately $1,019,000 and $3,314,000, compared to $873,000 and $3,822,000 for the three and nine months ended January 31, 2018, respectively. The decrease was primarily due to increase in revenues, hence increase in gross profit with lower operating expenses mainly due to lower general and administrative expenses we discussed above.

 
LIQUIDITY AND CAPITAL RESOURCES

Liquidity is the ability of a company to generate sufficient cash to meet its operational cash requirements.  

At January 31, 2019, we had working capital deficit of approximately $986,000, including cash of approximately $156,000, as compared to working capital deficit of approximately $482,000, including cash of approximately $1,101,000, at April 30, 2018. The approximate $945,000 decrease in our cash at January 31, 2019 from April 30, 2018 is primarily attributable to net cash used in operating activities and net cash used in investing activities for the purchase of property and equipment to improve our productivity offset by net cash provided by financing activities from loans. The Company's cash balance and revenues generated are not currently sufficient and cannot be projected to cover operating expenses for the next twelve months from the date of this report. These factors raise doubt as to the ability of the Company to continue as a going concern. Management's plans include attempting to improve its business profitability, its ability to generate sufficient cash flow from its operations to meet its operating needs on a timely basis, obtain additional working capital funds through debt financing, and restructure on-going operations to eliminate inefficiencies to raise cash balance in order to meet its anticipated cash requirements for the next twelve months from the date of this report. Management intends to make every effort to improve its current sales force as to further develop and expand the international markets for its new products as well as continuing with the current sources of funds to meet working capital needs on as needed basis.  There can be no assurance that these plans and arrangements will be successful.
 
Accounts receivable, net of allowance for doubtful accounts, including accounts receivable from related parties, decreased by approximately $926,000 during the nine months ended January 31, 2019, as a result of the decrease in accounts receivable from both the third parties and related parties as of January 31, 2019. The days for sales outstanding in accounts receivable increased to 29 days as of January 31, 2019, as compared to 18 days as of April 30, 2018. The days for sales outstanding in accounts receivable for third party sales increased to 20 days as of January 31, 2019, as compared to 14 days as of April 30, 2018.  We will reevaluate and categorize accounts receivable for sales and will target to improve our collection effort in accounts receivable for related party sales and accounts receivable for third party sales in the remainder of fiscal 2019.

Inventories at January 31, 2019, net of reserve for obsolescence, totaled approximately $13,416,000, as compared to $12,565,000 as of April 30, 2018. The slightly higher procurements of raw materials was still enough to meet our anticipated increase in demands since demands are raising slower than we originally anticipated.

Our accounts payable and accrued expenses were approximately $9,665,000 at January 31, 2019, a decrease of approximately $1,995,000 from April 30, 2018. We predicted the price of raw material will be increased based on information available to us and we increased in procurements of raw materials volume during the nine months ended January 31, 2019. This inventory has not yet been sold, partly due to the market demand not raising as much as we predicted, however the higher inventory balance will prepare us for our anticipated upcoming increase in demand.

Loans payable at January 31, 2019 and April 30, 2018 totaled approximately $14,994,000 and $9,990,000, respectively. These loans payable consisted of short-term loans of approximately $9,161,000 (RMB61,410,680) and long-term loans of $5,833,000 (RMB39,100,000) from multiple non-related individuals, which bear annual interest rates of 4 - 10%.  The maturity dates of the loans payable at January 31, 2019 range from March 6, 2019 to December 31, 2020. During the nine months ended January 31, 2019, the Company repaid approximately $430,000 of the prior year's loans payable and borrowed new loans amounting to $5,788,000.

- 24 -

Cash Flows Analysis
 
NET CASH FLOW USED IN OPERATING ACTIVITIES:

Net cash used in operating activities was approximately $6,690,000 during the nine months ended January 31, 2019, as compared to net cash used in operating activities of $2,443,000 in the same period in 2018.  The increase of  cash used in operating activities was primarily due to a net loss of approximately $3,314,000 adjusted and offset by non-cash items such as depreciation and amortization expenses of approximately $941,000, stock issued for employees' compensation of $716,000, $504,000 decrease in accounts receivable, $148,000 decrease in accounts receivable-related parties, offset by $1,522,000 increase in inventories, $1,227,000 increase in prepaid expense and other current assets, $2,867,000 decrease in accounts payable and accrued expenses, and $69,000 decrease in taxes payable.

Net cash used in operating activities was approximately $2,443,000 during the nine months ended January 31, 2018, as compared to net cash used in operating activities of $977,000 in the same period in 2017. The increase of  cash used in operating activities was primarily due to depreciation and amortization expenses of approximately $1,203,000, stock issued for employees' compensation of $920,000, loss on disposition of property and equipment of $285,000,  $2,063,000 increase in accounts payable and accrued expenses, and $1,715,000 decrease in prepaid expense and other current assets, offset by a net loss of approximately $3,822,000, $2,301,000 increase in inventories, $262,000 increase in accounts receivable, $1,989,000 increase in accounts receivable-related party, $38,000 decrease in taxes payables and a recovery of bad debts reserve of $217,000.
 
NET CASH FLOW USED IN INVESTING ACTIVITIES:

Net cash used in investing activities amounted to approximately $716,000 during the nine months ended January 31, 2019 due to capital expenditures for property and equipment.

Net cash used in investing activities amounted to approximately $706,000 during the nine months ended January 31, 2018 due to capital expenditures for property and equipment of approximately $708,000, offset by the proceeds received from disposal of equipment of approximately $2,000.
 
NET CASH FLOW PROVIDED BY FINANCING ACTIVITIES:

Net cash provided by financing activities amounted to approximately $6,382,000 in the nine months ended January 31, 2019, primarily consisted of proceeds from multiple non-related individual short-term and long-term loans of $5,788,000 and advances received from related parties of approximately $3,947,000, offset by repayment of short-term loans of $429,000 and repayment of related party advances of approximately $2,923,000.
 
Net cash provided by financing activities amounted to approximately $3,107,000 in the nine months ended January 31, 2018, primarily due to proceeds from loans of approximately $1,665,000 and repayment for the short-term loan of approximately $375,000. We also recorded advances received from related party as working capital, net of repayments made to related party advances. During the nine months ended January 31, 2018, we received advances from related parties totaling of approximately $5,069,000 for working capital purposes and we also made repayments to related parties of approximately $3,252,000.

CASH ALLOCATION BY COUNTRIES

The functional currency of our Chinese subsidiaries is the Chinese RMB. Substantially all of our cash is held in the form of RMB at financial institutions located in the PRC, where there is no equivalent of federal deposit insurance as in the United States. As a result, cash accounts at financial institutions in the PRC are not insured. We have not experienced any losses in such accounts as of January 31, 2019.

In 1996, the Chinese government introduced regulations which relaxed restrictions on the conversion of the RMB; however restrictions still remain, including but not limited to restrictions on foreign invested entities. Foreign invested entities may only buy, sell or remit foreign currencies after providing valid commercial documents at only those banks authorized to conduct foreign exchanges. Furthermore, the conversion of RMB for capital account items, including direct investments and loans, is subject to PRC government approval. Chinese entities are required to establish and maintain separate foreign exchange accounts for capital account items. We cannot be certain Chinese regulatory authorities will not impose more stringent restrictions on the convertibility of the RMB, especially with respect to foreign exchange transactions. Accordingly, cash on deposit in banks in the PRC is not readily deployable by us for purposes outside of the PRC. Our cash position by geographic area is as follow:
- 25 -


 
 
January 31,
2019
   
April 30,
2018
 
Country:
                       
United States
 
$
98,506
     
63.3
%
 
$
696
     
*
 
China (PRC)
   
57,188
     
36.7
%
   
1,100,052
     
100.0
%
Total cash and cash equivalents
 
$
155,694
     
100.0
%
 
$
1,100,748
     
100.0
%
*  Less than 0.1%
                               

Off Balance Sheet Arrangements

Under SEC regulations, we are required to disclose our off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, such as changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. An off-balance sheet arrangement means a transaction, agreement or contractual arrangement to which any entity that is not consolidated with us as a party, under which we have:

 
-
 
Any obligation under certain guarantee contracts,
 
-
 
Any retained or contingent interest in assets transferred to an unconsolidated entity or similar arrangement that serves as credit, liquidity or market risk support to that entity for such assets,
 
-
 
Any obligation under a contract that would be accounted for as a derivative instrument, except that it is both indexed to our stock and classified in stockholder's equity in our statement of financial position, and
 
-
 
Any obligation arising out of a material variable interest held by us in an unconsolidated entity that provides financing, liquidity, market risk or credit risk support to us, or engages in leasing, hedging or research and development services with us.
 
We do not have any off-balance sheet arrangements that we are required to disclose pursuant to these regulations. In the ordinary course of business, we enter into operating lease commitments, purchase commitments and other contractual obligations. These transactions are recognized in our financial statements in accordance with accepted accounting principles generally accepted in the U.S. ("U.S. GAAP").

CRITICAL ACCOUNTING POLICIES
 
The preparation of financial statements in conformity with U.S. GAAP requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The SEC has defined a company's critical accounting policies as the ones that are most important to the portrayal of the company's financial condition and results of operations, and which require the company to make its most difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Based on this definition, we have identified the critical accounting policies and judgments addressed below. We also have other key accounting policies, which involve the use of estimates, judgments and assumptions that are significant to understanding our results, which are described in Note 2 to our unaudited condensed consolidated financial statements. Although we believe that our estimates, assumptions and judgments are reasonable, they are based upon information presently available. Actual results may differ significantly from these estimates under different assumptions, judgments or conditions.  

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
Not applicable to smaller reporting company.
 
ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act") that are designed to ensure that information required to be disclosed by us in reports that we file under the Exchange Act is recorded, processed, summarized and reported as specified in the SEC's rules and forms and that such information required to be disclosed by us in reports that we file under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer ("CEO"), and our Chief Financial Officer ("CFO"), to allow timely decisions regarding required disclosure.
 
Our management, with the participation of our CEO and CFO, performed an evaluation of the effectiveness of our disclosure controls and procedures as of January 31, 2019.  
- 26 -


Based on this evaluation our management concluded that our disclosure controls and procedures were not effective as of January 31, 2019 such that the information relating to our company, required to be disclosed in our Securities and Exchange Commission reports (i) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (ii) is accumulated and communicated to our management, including our CEO, to allow timely decisions regarding required disclosure.
 
Management's Report on Internal Control over Financial Reporting
 
Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act. Our management is also required to assess and report on the effectiveness of our internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 ("Section 404"). As reported in our Form 10-K for the year ended April 30, 2018, management assessed the effectiveness of our internal control over financial reporting as of April 30, 2018 and, during our assessment, management identified significant deficiencies related to (i) the U.S. GAAP expertise of our internal accounting staff, (ii) our internal audit functions and (iii) a lack of segregation of duties within accounting functions. Although management believes that these deficiencies do not amount to a material weakness, our internal controls over financial reporting were not effective at April 30, 2018.

Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. As a result, we have not been able to take steps to improve our internal controls over financial reporting during the three months ended January 31, 2019. However, to the extent possible, we will implement procedures to assure that the initiation of transactions, the custody of assets and the recording of transactions will be performed by separate individuals.

A material weakness (within the meaning of PCAOB Auditing Standard No. 5) is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control over financial reporting that is less severe than a material weakness, yet important enough to merit attention by those responsible for oversight of the company's financial reporting.
 
In light of this significant deficiency, we performed additional analyses and procedures in order to conclude that our consolidated financial statements for the three months ended January 31, 2019 included in this quarterly report on Form 10-Q were fairly stated in accordance with the U.S. GAAP. Accordingly, management believes that despite our significant deficiency, our consolidated financial statements for the three months ended January 31, 2019 are fairly stated, in all material respects, in accordance with the U.S. GAAP.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation of our controls performed during the quarter ended January 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.


PART II - OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS.

None.

ITEM 1A.RISK FACTORS.

Risk factors describing the major risks to our business can be found under Item 1A, "Risk Factors", in our fiscal 2018 Annual Report on Form 10-K. There has been no material change in our risk factors from those previously discussed in the fiscal 2018 Annual Report on Form 10-K.

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES.

None.
- 27 -


ITEM 4.  MINE SAFETY DISCLOSURE.
 
None.
 
ITEM 5. OTHER INFORMATION.
 
None.
 
ITEM 6.  EXHIBITS
 
Exhibit No.
 
Description of Exhibit
 
31.1
 
Section 302 Certificate of Chief Executive Officer.*
 
31.2
 
Section 302 Certificate of Chief Financial Officer.*
 
32.1
 
Section 906 Certificate of Chief Executive Officer and Chief Financial Officer.*
101.INS
 
XBRL INSTANCE DOCUMENT**
101.SCH
 
XBRL TAXONOMY EXTENSION SCHEMA**
101.CAL
 
XBRL TAXONOMY EXTENSION CALCULATION LINKBASE**
101.DEF
 
XBRL TAXONOMY EXTENSION DEFINITION LINKBASE**
101.LAB
 
XBRL TAXONOMY EXTENSION LABEL LINKBASE**
101.PRE
 
XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE**
 
* - Filed herewith.
** - In accordance with Regulation S-T, the XBRL-formatted interactive data files that comprise Exhibit 101 to this Quarterly Report on Form 10-Q shall be deemed "furnished" and not "filed".

 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
SUNWIN STEVIA INTERNATIONAL, INC.
 
 
 
 
Dated: March 15, 2019
By: /s/ Dongdong Lin
 
Dongdong Lin,
 
Chief Executive Officer
 
 
 
 
Dated: March 15, 2019
By: /s/ Fanjun Wu 
 
Fanjun Wu, 
 
Chief Financial Officer 
 
- 28 -

Exhibit 31.1
 
Rule 13a-14(a)/15d-14(a) Certification
 
I, Dongdong Lin, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the period ended January 31, 2019 of Sunwin Stevia International, Inc.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15-d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

March 15, 2019
/s/ Dongdong Lin
 
Dongdong Lin,
 
Chief Executive Officer
(Principal Executive Officer)


Exhibit 31.2
 
Rule 13a-14(a)/15d-14(a) Certification

I, Fanjun Wu, certify that:

1. I have reviewed this quarterly report on Form 10-Q for the period ended January 31, 2019 of Sunwin Stevia International, Inc.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15-d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
March 15, 2019
/s/ Fanjun Wu
 
Fanjun Wu,
 
Chief Financial Officer
(Principal Financial and Accounting Officer)
 

Exhibit 32.1

Section 1350 Certification

In connection with the quarterly report of Sunwin Stevia International, Inc. (the "Company") on Form 10-Q for the period ended January 31, 2019 as filed with the Securities and Exchange Commission (the "Report"), I, Dongdong Lin, Chief Executive Officer of the Company, and I, Fanjun Wu, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. SS. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
 
March 15, 2019
/s/ Dongdong Lin
 
Dongdong Lin,
 
Chief Executive Officer
 
 
March 15, 2019
/s/ Fanjun Wu
 
Fanjun Wu,
 
Chief Financial Officer
 
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.